RxDoctor Payments Data

Ali Moshiri, MD

Psychiatry · Amherst, MANPI 1679525786

Payments from drug & device makers

$3,289in general payments, 2019–2025

Across 135 payments — averaging $24.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$750
  • Alkermes, Inc.$515
  • Otsuka America Pharmaceutical, Inc.$494
  • Johnson & Johnson$490
  • AbbVie$360
  • Neurocrine Biosciences, Inc.$303
  • plus $378 from 6 others

What the payments were for

  • Food & beverage$3,289100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,289 in reported general payments places this provider in the 85th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts

Medicare billing

Part B allowed, 2024
$74,903
Medicare patients
245
Services billed
829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate61$202,813
LybalviOlanzapine/Samidorphan Malate13$19,730
AdderallDextroamphetamine/Amphetamine21$12,980
FetzimaLevomilnacipran Hcl22$10,854
Chlorpromazine Hcl74$9,685
AmbienZolpidem Tartrate12$7,612
Divalproex Sodium ErDivalproex Sodium147$6,081
Clozapine52$4,838
Oxcarbazepine88$4,725
Risperidone288$4,175
Quetiapine Fumarate102$3,849
Trazodone Hcl274$3,347
Paliperidone ErPaliperidone38$3,211
Olanzapine150$3,044
Aripiprazole40$2,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$490$202,81361 claims
Alkermes, Inc.Lybalvi$515$19,73013 claims
Takeda Pharmaceuticals U.S.A., Inc.Adderall$42$12,98021 claims
AbbVieFetzima$360$10,85422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,431 psychiatry providers in Massachusetts.

Other psychiatry in Amherst

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →